Published in J Clin Immunol on July 01, 1999
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A (2000) 2.11
Associations between inflammation and cognitive function in African Americans and European Americans. J Am Geriatr Soc (2014) 2.07
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol (2007) 2.05
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J Neurol (2008) 1.53
Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs (2014) 1.49
Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging (2010) 1.45
Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation (2008) 1.45
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Tumor necrosis factor-alpha at the crossroads of neuronal life and death during HIV-associated dementia. J Neurochem (2003) 1.31
TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J Neuroinflammation (2012) 1.29
Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci (2006) 1.24
Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med (2010) 1.24
Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation (2012) 1.13
Trisomy 21 and the brain. J Neuropathol Exp Neurol (2004) 1.11
Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol (2008) 1.08
Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry (2004) 1.04
Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front Aging Neurosci (2014) 1.02
Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med (2015) 0.99
Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol (2014) 0.98
Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J Neurosci (2008) 0.95
Differences in abundances of cell-signalling proteins in blood reveal novel biomarkers for early detection of clinical Alzheimer's disease. PLoS One (2011) 0.94
CSF Biomarkers for Alzheimer's Disease Diagnosis. Int J Alzheimers Dis (2010) 0.94
An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin. Proc Natl Acad Sci U S A (2006) 0.92
Cerebrospinal fluid markers of neuroinflammation in delirium: a role for interleukin-1β in delirium after hip fracture. J Psychosom Res (2014) 0.91
Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease. Clin Chem (2009) 0.90
Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. Life Sci (2014) 0.87
Tumour necrosis factor alpha-induced neuronal loss is mediated by microglial phagocytosis. FEBS Lett (2014) 0.86
Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2012) 0.86
Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship. Neurocase (2012) 0.86
Characterisation of amyloid-induced inflammatory responses in the rat retina. Exp Brain Res (2011) 0.85
Amyloid-β reduces the expression of neuronal FAIM-L, thereby shifting the inflammatory response mediated by TNFα from neuronal protection to death. Cell Death Dis (2015) 0.85
Cardiovascular dementia - a different perspective. Open Biochem J (2010) 0.83
TNF-α/NF-κB signaling in the CNS: possible connection to EPHB2. J Neuroimmune Pharmacol (2013) 0.81
Defining the Microglia Response during the Time Course of Chronic Neurodegeneration. J Virol (2015) 0.80
Neuronal c-Abl activation leads to induction of cell cycle and interferon signaling pathways. J Neuroinflammation (2012) 0.80
Declines in inflammation predict greater white matter microstructure in older adults. Neurobiol Aging (2014) 0.80
Atorvastatin prevents amyloid-β peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway. Acta Pharmacol Sin (2014) 0.80
The effect of chronic periodontitis on serum levels of tumor necrosis factor-alpha in Alzheimer disease. Dent Res J (Isfahan) (2014) 0.80
Comparison of cerebrospinal fluid biomarkers between idiopathic normal pressure hydrocephalus and subarachnoid hemorrhage-induced chronic hydrocephalus: a pilot study. Med Sci Monit (2012) 0.79
Intereleukin-10 promoter polymorphism in mild cognitive impairment and in its clinical evolution. Int J Alzheimers Dis (2010) 0.79
Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly. PLoS One (2012) 0.79
The "Alzheimer's disease signature": potential perspectives for novel biomarkers. Immun Ageing (2011) 0.78
Brain Atrophy, Anti-Smooth Muscle Antibody and Cognitive Impairment: An Association Study. Aging Dis (2015) 0.77
Cerebrospinal fluid levels of inflammation, oxidative stress and NAD+ are linked to differences in plasma carotenoid concentrations. J Neuroinflammation (2014) 0.77
Combining select neuropsychological assessment with blood-based biomarkers to detect mild Alzheimer's disease: a molecular neuropsychology approach. J Alzheimers Dis (2014) 0.77
The influence of tumour necrosis factor- α (TNF-α) on amyloid-β (Aβ)-degrading enzymes in vitro. Int J Mol Epidemiol Genet (2011) 0.77
16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer's Post-Mortem Brain. Front Aging Neurosci (2017) 0.76
Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. J Cereb Blood Flow Metab (2016) 0.76
Intranasal brain delivery of cationic nanoemulsion-encapsulated TNFα siRNA in prevention of experimental neuroinflammation. Nanomedicine (2016) 0.75
Heparan sulfate proteoglycan induces the production of NO and TNF-alpha by murine microglia. Immun Ageing (2005) 0.75
CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection. Biomed Res Int (2016) 0.75
Adenosine A(2A) Receptor and IL-10 in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment. Int J Alzheimers Dis (2011) 0.75
Folic acid supplementation improves cognitive function by reducing the levels of peripheral inflammatory cytokines in elderly Chinese subjects with MCI. Sci Rep (2016) 0.75
Subventricular zone neural progenitors reverse TNF-alpha effects in cortical neurons. Stem Cell Res Ther (2015) 0.75
Amyloid Beta, TNFα and FAIM-L; Approaching New Therapeutic Strategies for AD. Front Neurol (2014) 0.75
Insight into the Molecular Imaging of Alzheimer's Disease. Int J Biomed Imaging (2016) 0.75
Selective induction of alternatively spliced FynT isoform by TNF facilitates persistent inflammatory responses in astrocytes. Sci Rep (2017) 0.75
Associations Between Serum Inflammatory Markers and Hippocampal Volume in a Community Sample. J Am Geriatr Soc (2016) 0.75
The immune state of bulbectomized mice. Dokl Biol Sci (2004) 0.75
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 16.92
Production of hybridoma growth factor by human monocytes. Eur J Immunol (1987) 7.99
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A (1989) 5.97
Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res (1973) 4.65
Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature (1995) 4.18
A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem (1993) 3.81
Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol (1988) 3.51
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol (1995) 3.23
Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett (1987) 3.13
Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron (1994) 2.84
Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci U S A (1993) 2.62
Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A (1989) 2.56
Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A (1989) 2.48
Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? Immunol Today (1991) 2.41
Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci U S A (1995) 2.24
On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol (1989) 2.20
Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron (1994) 2.09
The proto-oncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell (1993) 2.01
Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol (1988) 1.89
A growth-factor dependent B-cell hybridoma. Curr Top Microbiol Immunol (1986) 1.79
Immune system response in Alzheimer's disease. Can J Neurol Sci (1989) 1.75
Monokine production by microglial cell clones. Eur J Immunol (1989) 1.64
Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke (1995) 1.58
Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol (1997) 1.51
DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci (1996) 1.41
Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol (1996) 1.26
Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J Neurosci (1996) 1.22
Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neurosci Lett (1989) 1.07
Beta-amyloid induces apoptosis in human-derived neurotypic SH-SY5Y cells. Brain Res (1996) 1.07
A new rating scale for dementia syndromes. Arch Gerontol Geriatr (1982) 1.05
Cytokine regulation of neuronal survival. J Neurochem (1992) 1.03
Tumor necrosis factor facilitates regeneration of injured central nervous system axons. Brain Res (1991) 0.99
Increased immunoreactivity for Jun- and Fos-related proteins in Alzheimer's disease: association with pathology. Exp Neurol (1994) 0.97
Localization of Fas antigen mRNA induced in postischemic murine forebrain by in situ hybridization. Brain Res Mol Brain Res (1995) 0.87
Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol (1996) 0.86
Effect of tumor necrosis factor alpha and beta on human oligodendrocytes and neurons in culture. Int J Dev Neurosci (1995) 0.83
The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res Immunol (1993) 0.82
Decreased lumbar cerebrospinal fluid levels of monoamine metabolites in vascular dementia. Int Psychogeriatr (1996) 0.78
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods (1983) 6.71
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med (2001) 5.06
The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine arthritis model. Infect Immun (1993) 4.00
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol (1995) 3.23
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Histopathological and serological progression of experimental Staphylococcus aureus arthritis. Infect Immun (1992) 2.64
Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl (2000) 2.56
The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis. Infect Immun (1994) 2.44
Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology (2008) 2.41
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Experimental Staphylococcus aureus arthritis in mice. Infect Immun (1991) 2.24
Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res (2001) 2.19
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect Immun (1997) 2.08
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett (2001) 2.05
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett (2001) 1.89
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Incidence of ROP in two consecutive Swedish population based studies. Br J Ophthalmol (2002) 1.86
CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand (2007) 1.85
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect Immun (1997) 1.80
Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology (2010) 1.78
White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand (1991) 1.77
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. Arthritis Rheum (1990) 1.75
CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology (2005) 1.73
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord (2003) 1.67
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect Immun (2000) 1.65
Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol (2009) 1.64
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med (1999) 1.61
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J Neurol Neurosurg Psychiatry (2003) 1.58
Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke (1995) 1.58
Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium. Eur Respir J (2005) 1.56
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
Alpha-toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in murine septic arthritis. Infect Immun (1999) 1.52
Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol (1997) 1.51
A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology (1998) 1.50
White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology (2004) 1.47
Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol Scand (1994) 1.44
White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology (2010) 1.44
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology (2007) 1.43
Cerebrospinal fluid monoamine metabolites and atmospheric pressure. Biol Psychiatry (1996) 1.39
Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure. Eur Respir J (2005) 1.39
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 1.38
Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.38
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology (2006) 1.37
A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta Neurol Scand (1987) 1.36
Genistein as an anti-inflammatory agent. Inflamm Res (2003) 1.35
Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Invest (1998) 1.35
Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci U S A (1994) 1.33
APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology (2004) 1.33
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett (1999) 1.32
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res (2005) 1.32
Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shock syndrome toxin-1-producing staphylococci. Eur J Immunol (1994) 1.32
White matter changes and late-life depressive symptoms: longitudinal study. Br J Psychiatry (2007) 1.31
Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31
The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun (2001) 1.30
The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis. Immunology (1998) 1.30
The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry (2005) 1.30
Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand (1990) 1.29
Mice with the xid B cell defect are less susceptible to developing Staphylococcus aureus-induced arthritis. J Immunol (1995) 1.28
CT evaluation of coverage and congruency of the hip prior to osteotomy. Clin Orthop Relat Res (1988) 1.28
Deep frontal and periventricular age related white matter changes but not basal ganglia and infratentorial hyperintensities are associated with falls: cross sectional results from the LADIS study. J Neurol Neurosurg Psychiatry (2009) 1.28
Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis. Arthritis Rheum (1996) 1.27
Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice. Clin Exp Immunol (1990) 1.26
Impact of interferon-gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. J Immunol (1995) 1.26
Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 1.26
Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus (2000) 1.26
A demineralization procedure for immunohistopathological use. EDTA treatment preserves lymphoid cell surface antigens. J Immunol Methods (1986) 1.25
White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol (1998) 1.25
Reverse enzyme-linked immunospot assay (RELISPOT) for the detection of cells secreting immunoreactive substances. J Immunol Methods (1984) 1.21
Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol (1998) 1.21
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm (Vienna) (2000) 1.20
Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci (2005) 1.20
Role of T lymphocytes in experimental Staphylococcus aureus arthritis. Scand J Immunol (1994) 1.19
Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res (2001) 1.19